Douglas Eby

Amministratore Delegato presso Cambridge Science Corp.

Health Technology

Profilo

Douglas Eby currently works at Cambridge Science Corp., as President, Chief Executive Officer & Director and Kyttaro Ltd., as Chief Executive Officer & Director.

Posizioni attive di Douglas Eby

Società	Posizione	Inizio
Cambridge Science Corp. Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA.	Amministratore Delegato	-
KYTTARO Ltd. KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby.	Amministratore Delegato	-

Tutte le posizioni attive di Douglas Eby

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Douglas Eby

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Cambridge Science Corp. Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA.	Health Technology
KYTTARO Ltd. KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby.	Health Technology